Welcome

Please select your view

banner-28-1800x424jpg

World’s first non-invasive melanoma test

New Australian partnership forms to bring world’s first non-invasive melanoma test to market

 

Australian Clinical Labs and Geneseq Biosciences (Geneseq) have announced they will partner to bring the first non-invasive melanoma test to market under the trade mark Melaseq™.

Melaseq will offer over two million Australians at high-risk of developing melanoma in their lifetime access to a simple blood test to detect melanoma signatures in their blood. Melaseq is also suited to tissue samples testing.

With no specific solid tissue, blood or genetic detection tests available worldwide, doctors will welcome Melaseq for its accuracy and ability to improve clinical decision making and the monitoring of patients at risk of developing melanoma or those with re-emerging melanoma.

Once fully commercialised, Melaseq will for the first time, offer physicians a diagnostic tool to monitor for early signs of melanoma recurrence, potentially allowing life-saving treatment to start earlier.

The backing of Clinical Labs achieves an important milestone for Geneseq, a wholly owned Australian company. As Australia’s largest privately-held pathology company, Geneseq can accelerate additional testing and validation work at the scale required to bring Melaseq to the market.

Group CEO and Managing Director of Clinical Labs, Melinda McGrath said the new partnership is another demonstration of our strategy to innovate and grow through scientific leadership, market leading technology and talented people. “We are delighted to be part of the early detection of melanoma. Australia has the largest incidence of skin cancer in the world and we want to this to change. Partnering with Geneseq Biosciences presents an exciting opportunity to find new ways to detect and prevent melanoma sooner,” she said.

Ryan Van Laar PhD, CEO of Geneseq Biosciences said, “We are thrilled to be partnering with Clinical Labs, a company highly regarded as an early adopter of new technologies, such as precision medicine. This agreement gives us access to a world-class clinical and bio-specimen network, in addition to the reimbursement, regulatory, and commercial expertise necessary to make Melaseq a success,” Dr Van Laar said.

It is anticipated that Melseq will be available as a tissue sample test in 2020, followed by the blood test in 2021.

More information about the research: www.geneseq.com.au

Media contact: Justine Larkins, +(61) 421 883 766